Skip to content

    Saakshi Medtech

    Capital Goods
    Industrials
    View SAAKSHI earnings calls

    Overview

    Price

    Market Cap

    ₹530 Cr

    Sector

    Capital Goods

    Industrials

    Rank

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital333318181818
    Reserves1518274076808793
    Borrowings1922162018182425
    Other Liabilities1114193119151921
    Total Liabilities48566593131131148157
    AssetsFixed Assets2222263462607683
    CWIP0000013910
    Investments00000000
    Other Assets2634395968586264
    Total Assets48566593131131148157

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26
    ActivitiesCash from Operating11011118318
    Cash from Investing-6-1-5-11-31-15-25
    Cash from Financing-32-7236-16
    SummaryCapital Expenditure
    Free Cash Flow4-150-24-12-8
    FCF Margin

    Valuation

    Assumptions

    Current — SAAKSHI
    Price
    ₹266
    EPS (TTM)
    ₹9.63
    PE (TTM)
    27.6
    Profit growth

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (17.5×) and current (27.6×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹266
    vs
    Fair value · 15% return
    ₹120
    55%Overvalued

    At 10% growth and a 18× exit, ₹266 only delivers your return if you pay ₹120. The price is currently baking in 27% growth.

    EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 18×.

    YearGrowthEPS (₹)
    FY2710.0%10.59
    FY2810.0%11.65
    FY2910.0%12.82
    FY3010.0%14.10
    FY3110.0%15.51
    FY328.0% ·fade16.75
    FY336.0% ·fade17.75

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Saakshi Medtech

    Guides on how to read this kind of business and the numbers that matter.